Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TREAT OA

Financiado

Cerrado

Translational Research in Europe Applied Technologies for Osteoarthritis

TREAT-OA will address the need for better treatment and diagnostics for osteoarthritis (OA) - the most common cause of disability in Europe. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there ye... ver más

30/06/2013

KINGS COLLEGE LOND...

17M€

Presupuesto del proyecto: 17M€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-06-30 No tenemos la información de la convocatoria

0% 72% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

KINGS COLLEGE LONDON

0.00€ | Lider

TIG

N.D. | Participante

UOXF

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

O-POINTED Osteoarthritis patient cohorts in the dish personalised ce... 71K€ Cerrado

PID2021-126469OB-C21 HYBRID REPRESENTATIONS OF OA: FROM BIOLOGY TO PATIENT CHARAC... 156K€ Cerrado

OACTIVE Advanced personalised multi scale computer models preventin... 5M€ Cerrado

RABIOPRED RABIOPRED Clinical validation of BIOmarker assay to PREDic... 5M€ Cerrado

SQUEEZE Maximising Impact of Prescription Drugs in Rheumatoid Arthri... 9M€ Cerrado

PID2019-107188RB-C21 ESTUDIOS GENETICOS Y FUNCIONALES HACIA APROXIMACIONES TERAPE... 145K€ Cerrado

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 17M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto TREAT-OA will address the need for better treatment and diagnostics for osteoarthritis (OA) - the most common cause of disability in Europe. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, costs of therapeutic trials and the development of disease modifying drugs. TREAT-OA represents a large-scale collaborative, integrated, trans-disciplinary project utilising a resource of 28,000 OA phenotyped subjects with available genome-wide association scan data as well as leading basic science laboratories and technologies. This is the largest study of its kind that will address the generalisability and utility of genetic and biochemical risk factors throughout the EU. The key objectives of TREAT-OA are to: 1 Identify genes and biochemical markers consistently associated with risk and progression of OA 2 Use such genes to further our understanding of the molecular pathways involved in disease aetiology 3 Analyze pathways to identify targets for pharmacological intervention 4 Develop transgenic animal laboratory OA model systems . 5 Develop a panel of genetic and biochemical diagnostics for risk and progression of OA 6 Disseminate results from this extensive research at large and use results and technologies for training within the EU TREAT-OA will help develop European clinical and scientific excellence in the diagnosis and treatment of OA. The novel pathways in disease aetiology discovered will translate into novel drug targets and protein therapeutics for OA. The development of in vitro and in vivo assays will provide a comprehensive technology platform enabling the discovery and development of disease modifying drugs for OA. TREAT-OA will also make a major impact on the disease via a diagnostic panel of genes and biochemical markers for selecting severe cases and rapidly progressing individuals.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores